SOUTH SAN FRANCISCO, CA & VANCOUVER, BC – ESSA Pharma Inc. (“ESSA”, or the “Company”) (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate… Read More
Technologies work together to simplify single-cell workflows, saving time for academic researchers. Combined VIA Extractor and LeviCell system addresses key challenges in sample preparation, minimizing single-cell damage and stress. Two… Read More
Treatment with the once-daily vanza triple CFTR modulator regimen met all primary and key secondary endpoints in two randomized controlled trials in people with CF ages 12 years and older… Read More
The Research Approval Processes Project (RAPP) has received support from the Leadership Council, a council of Health Authority Chief Executive Officers and Ministry of Health leadership. Recognizing the pivotal role… Read More
No serious or treatment related adverse events in either the first or second cohort Second cohort demonstrated an average 60% reduction in Dysphasia Likert score and an average 80% reduction… Read More
